AKBA Akebia Therapeutics, Inc.

Nasdaq akebia.com


$ 2.78 $ 0.01 (0.36 %)    

Tuesday, 14-Oct-2025 16:35:26 EDT
QQQ $ 598.50 $ -4.01 (-0.67 %)
DIA $ 463.08 $ 2.03 (0.44 %)
SPY $ 662.74 $ -0.81 (-0.12 %)
TLT $ 90.69 $ 0.29 (0.32 %)
GLD $ 382.95 $ 2.70 (0.71 %)
$ 2.79
$ 2.75
$ 2.74 x 2
$ 2.84 x 52
$ 2.70 - $ 2.84
$ 1.30 - $ 4.08
1,652,575
na
739.75M
$ 1.35
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 03-13-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-14-2024 12-31-2023 10-K
8 11-08-2023 09-30-2023 10-Q
9 08-28-2023 06-30-2023 10-Q
10 05-08-2023 03-31-2023 10-Q
11 03-10-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 05-09-2022 03-31-2022 10-Q
15 03-01-2022 12-31-2021 10-K
16 11-04-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-10-2021 03-31-2021 10-Q
19 02-25-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-10-2020 06-30-2020 10-Q
22 05-05-2020 03-31-2020 10-Q
23 03-12-2020 12-31-2019 10-K
24 11-12-2019 09-30-2019 10-Q
25 08-08-2019 06-30-2019 10-Q
26 05-09-2019 03-31-2019 10-Q
27 03-26-2019 12-31-2018 10-K
28 11-08-2018 09-30-2018 10-Q
29 08-08-2018 06-30-2018 10-Q
30 05-09-2018 03-31-2018 10-Q
31 03-12-2018 12-31-2017 10-K
32 11-08-2017 09-30-2017 10-Q
33 08-08-2017 06-30-2017 10-Q
34 05-09-2017 03-31-2017 10-Q
35 03-06-2017 12-31-2016 10-K
36 11-09-2016 09-30-2016 10-Q
37 08-08-2016 06-30-2016 10-Q
38 05-05-2016 03-31-2016 10-Q
39 03-14-2016 12-31-2015 10-K
40 11-09-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 akebia-therapeutics-q2-sales-62472m-beat-47637m-estimate

Akebia Therapeutics (NASDAQ:AKBA) reported quarterly sales of $62.472 million which beat the analyst consensus estimate of $47....

 akebia-therapeutics-initiates-post-marketing-study-to-identify-additional-potential-benefits-of-vafseo

Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted b...

 akebia-therapeutics-announces-publication-in-jasn-of-us-and-non-us-subgroup-analyses-from-vadadustat-global-phase-3-trials-showing-comparable-safety-and-efficacy-in-dialysis-dependent-ckd-patients-and-highlighting-elevated-mace-risk-in-us-nondialysis-dependent-ckd-patients

Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted b...

 hc-wainwright--co-assumes-akebia-therapeutics-at-buy-announces-price-target-of-8

HC Wainwright & Co. analyst Matthew Caufield assumes Akebia Therapeutics (NASDAQ:AKBA) with a Buy rating and announces P...

 akebia-therapeutics-q1-eps-003-beats-004-estimate-sales-5734m-beat-4488m-estimate

Akebia Therapeutics (NASDAQ:AKBA) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $...

 hc-wainwright--co-reiterates-buy-on-akebia-therapeutics-maintains-75-price-target

HC Wainwright & Co. analyst Ed Arce reiterates Akebia Therapeutics (NASDAQ:AKBA) with a Buy and maintains $7.5 price tar...

 akebia-therapeutics-announces-committee-for-medicinal-products-for-human-use-of-the-european-medicines-agency-has-adopted-a-positive-opinion-recommending-the-european-commission-to-approve-xoanacyl-for-treatment-of-concomitant-elevated-serum-phosphorous-and-iron-deficiency-in-adult-patients-with-chronic-kidney-disease

Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted b...

 jefferies-initiates-coverage-on-akebia-therapeutics-with-buy-rating-announces-price-target-of-6

Jefferies analyst Roger Song initiates coverage on Akebia Therapeutics (NASDAQ:AKBA) with a Buy rating and announces Price T...

 reported-earlier-akebia-therapeutics-prices-50m-public-offering-of-25m-common-shares-at-2share

The gross proceeds to Akebia from the Offering, before deducting underwriting discounts, commissions and other offering expense...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION